Action 603520 ZHEJIANG STARRY PHARMACEUTICAL CO.,LTD.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Zhejiang Starry Pharmaceutical Co.,Ltd.

Actions

603520

CNE1000026N8

Cours en clôture Shanghai S.E.
Autres places de cotation
 00:00:00 10/05/2024 		Varia. 5j. Varia. 1 janv.
12,64 CNY -2,62% Graphique intraday de Zhejiang Starry Pharmaceutical Co.,Ltd. +0,56% -10,23%
29/04 Zhejiang Starry Pharmaceutical Co. publie ses résultats pour le premier trimestre clos le 31 mars 2024 CI
29/04 Zhejiang Starry Pharmaceutical Co. publie ses résultats pour l'exercice clos le 31 décembre 2023 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Hu Jinsheng agreed to acquire 36% stake in Xianju Juhe Financial Services Co., Ltd. from Zhejiang Starry Pharmaceutical Co.,Ltd. for CNY 19.8 million.
Shanghai Ddsome Laboratories Co., Ltd announced that it has received funding from Zhejiang Huahai Pharmaceutical Co., Ltd., Zhejiang Starry Pharmaceutical Co.,Ltd.
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
Shanghai Ddsome Laboratories Co., Ltd announced that it expects to receive CNY 28 million in funding from Zhejiang Starry Pharmaceutical Co.,Ltd.
Starry Pharma’s Generic X-Ray Contrast Agent Gets Marketing Approval
Zhejiang Starry Pharma’s CFO Resigns
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
Zhejiang Starry Pharmaceutical Co.,Ltd. agreed to acquire 18% Shanghai Starry Pharmaceutical Co., Ltd. from Jiaxing Juli Stellite Equity Investment Partnership.
Zhejiang Starry Pharmaceutical Co.,Ltd. announced that it expects to receive CNY 2.05 billion in funding
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
Zhejiang Zhumei Import and Export Group Co., Ltd agreed to acquire Zhejiang Xianju Thermal Power Co., Ltd from Zhejiang Starry Pharmaceutical Co.,Ltd. for CNY 35 million.
Zhejiang Starry Pharmaceutical Co.,Ltd.(SHSE:603520) dropped from Shanghai Stock Exchange Health Care Sector Index
Zhejiang Hisyn Pharmaceutical Co., Ltd. announced that it has received CNY 110.2637 million in funding from Zhejiang Starry Pharmaceutical Co.,Ltd.
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 603520
  4. Actualités Zhejiang Starry Pharmaceutical Co.,Ltd.
  5. Autres langues